Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER studyPierFranco Conte, Valentina Guarneri, Antonio Frassoldati et al.|Annals of Oncology|2018Cited by 157
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant studyValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Annals of Oncology|2019Cited by 97
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Gabriella Moretti et al.|The Lancet Oncology|2018Cited by 88
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Paolo Bruzzi, Mauro Mansutti et al.|The Lancet Oncology|2021Cited by 86
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni et al.|BMC Medicine|2019Cited by 25